Casey Collins

Casey Collins

Auto-generated profile, based on publicly available information

Casey Collins

The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGabriel Balmus
Gabriel Balmus
DLDelphine Larrieu
Delphine Larrieu
ABAna C. Barros
Ana C. Barros
CCCasey Collins
Casey Collins
MAMonica Abrudan
Monica Abrudan
SJStephen P. Jackson
Stephen P. Jackson
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare, but devastating genetic disease characterized by segmental premature aging, with cardiovascular disease being the main cause of death. Cells from HGPS patients accumulate progerin, a permanently farnesylated, toxic form of Lamin A, disrupting the nuclear shape and chromatin organization, leading to DNA-damage accumulation and senescence. Therapeutic approaches targeting farnesylation or aiming to reduce progerin levels have provided only partial health improvements. Recently, we identified Remodelin, a small-molecule agent that leads to amelioration of HGPS cellular defects through inhibition of the enzyme N-acetyltransferase 10 (NAT10). Here, we show the preclinical data demonstrating that targeting NAT10 in vivo, either via chemical inhibition or genetic depletion, significantly enhances the healthspan in a Lmna G609G HGPS mouse model. Collectively, the data provided here highlights NAT10 as a potential therapeutic target for HGPS.

18 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGabriel Balmus
Gabriel Balmus
DLDelphine Larrieu
Delphine Larrieu
ABAna C. Barros
Ana C. Barros
CCCasey Collins
Casey Collins
MAMonica Abrudan
Monica Abrudan
SJStephen P. Jackson
Stephen P. Jackson